Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer

BJU International

Volumn 110, Issue 8, 2012, Pages 1116-1121

  Westover, Kenneth ^a   Chen, Ming Hui ^b   Moul, Judd ^c   Robertson, Cary ^c   Polascik, Thomas ^c   Dosoretz, Daniel ^d   Katin, Michael ^d   Salenius, Sharon ^d   D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d 21ST CENTURY ONCOLOGY   (United States)

Author keywords

hormonal therapy; prostate cancer; radical prostatectomy

Indexed keywords

ANTIANDROGEN; CESIUM 131; GONADORELIN AGONIST; IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROSTATE TUMOR; SURVIVAL RATE;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 84871870016     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11012.x     Document Type: Article

References (24)

1. Stephenson AJ, Kattan MW, Eastham JA, et al,. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009; 27: 4300-5
2. Pierorazio PM, Guzzo TJ, Han M, et al,. Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology 2010; 76: 715-21
3. Thompson IM, Tangen CM, Paradelo J, et al,. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956-62
4. Choi S, Wallner KE, Merrick GS, Cavanagh W, Butler WM,. Treatment margins predict biochemical outcomes after prostate brachytherapy. Cancer J 2004; 10: 175-80
5. Kollmeier MA, Stock RG, Stone N,. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 2003; 57: 645-53
6. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW,. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-7
7. D'Amico AV, Chen M-H, Renshaw AA, Loffredo M, Kantoff PW,. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008; 299: 289-95
8. Antoch J,. A Guide to Chi-Squared Testing: Greenwood, P.E. and Nikulin, M.S. New York: John Wiley & Sons, Inc.pp. 280 +XII, ISBN 0-471-55779-X. AMS 1991 Classification: 62-02, 62F03, 62H15. Comput Stat Data Anal 1997; 23: 565-6
9. Gaynor JJ, Feuer EJ, Tan CC, et al,. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc 1993; 88: 400-9
10. Gray RJ,. A class of K-Sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-54
11. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509
12. D'Amico AV, Whittington R, Malkowicz SB, et al,. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74
13. Critz FA, Williams WH, Benton JB, Levinson AK, Holladay CT, Holladay DA,. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 2000; 163: 1085-9
14. Zelefsky MJ, Eastham JA, Cronin AM, et al,. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 2010; 28: 1508-13
15. Yu HH, Song DY, Tsai YY, Thompson T, Frassica DA, DeWeese TL,. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy. Urology 2007; 70: 111-6
16. D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP,. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer. J Urol 2001; 165: 126-9
17. Lee IH, Roberts R, Shah RB, Wojno KJ, Wei JT, Sandler HM,. Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer. Int J Radiat Oncol Biol Phys 2007; 68: 1059-64
18. Lotan Y, Shariat SF, Khoddami SM, et al,. The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy. J Urol 2004; 171: 2209-14
19. D'Amico AV, Keshaviah A, Manola J, et al,. Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 581-7
20. D'Amico AV, Chen M-H, Roehl KA, Catalona WJ,. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125-35
21. Palma D, Tyldesley S, Pickles T,. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy. Cancer 2008; 112: 1941-8
22. D'Amico AV, Hui-Chen M, Renshaw AA, et al,. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol 2006; 176: S11-5
23. D'Amico AV, Renshaw AA, Sussman B, et al,. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005; 294: 440-7
24. D'Amico AV, Chen M-H, Malkowicz SB, et al,. Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml or less. J Urol 2002; 167: 2025-31